Sanofi’s immunization strategy is taking shape, owing to an authorization that could drive the company and its partner AstraZeneca to the forefront of the respiratory syncytial virus (RSV) treatment battle. The FDA approved Sanofi and AstraZeneca’s monoclonal antibody Beyfortus, also known as nirsevimab, as a preve...
Find MoreNovartis signs USD 2.1Billion for Endocyte acquisition Novartis has inked USD 2.1 billion agreement to takeover Endocyte. Endocyte, a biopharmaceutical company, headquartered in Indiana, licensed the cancer drug that catches Novartis’ eye for USD 12 million. Endocyte was in the stagnation when it held its recovery h...
Find MoreCharles River to fuel hit discovery with AstraZeneca high-throughput collaboration After collaborating with AstraZeneca Charles River is now looking forward to strengthening its high-throughput screening capabilities (HTC) with the help of highly advance AstraZeneca technology. Now the company is able to offer the ...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.